Windlas Biotech Limited has received a show cause notice from the Office of the Commissioner, Food Safety & Drug Administration (Uttarakhand) on February 9, 2026, resulting in the temporary suspension of codeine-containing cough syrup manufacturing. The company disclosed this development through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Action Details

The Food Safety & Drug Administration authority has specifically targeted the manufacturing of codeine-containing cough syrup products. The company has confirmed that it is in the process of submitting a detailed response to the show cause notice within the stipulated timelines as required by the regulatory authority.

Financial Impact Assessment

The suspension carries significant financial implications for the pharmaceutical company:

Operational Continuity

The company has emphasized that the impact is limited exclusively to codeine-based cough syrups. All other manufacturing operations and product lines remain unaffected and continue normal production schedules. This targeted suspension allows the company to maintain most of its operational capacity while addressing the specific regulatory concerns.

Company Response and Commitment

Windlas Biotech has reiterated its commitment to maintaining the highest quality and compliant manufacturing standards across all its facilities. The company stated it will continue strengthening its compliance framework on an ongoing basis to prevent similar regulatory issues in the future.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary and compliance officer, Ananta Narayan Panda, signed the regulatory filing on February 10, 2026.

Windlas Biotech Limited has announced significant changes in its directorate structure, re-appointing three key directors for five-year terms following a Board meeting held on February 5, 2026. The appointments were made based on recommendations from the Nomination and Remuneration Committee and are subject to shareholder approval.

Director Re-appointments Overview

The pharmaceutical company has re-appointed three directors to ensure continuity in leadership and strategic direction:

Leadership Profiles

Ashok Kumar Windlass - Whole-time Director

Mr. Ashok Kumar Windlass, the Promoter and Founder of the company, brings extensive experience spanning over 56 years in the manufacturing and pharmaceutical industries. Key highlights of his profile include:

• Holds a diploma in Civil Engineering from Government Polytechnic, Ambala City
• Initially appointed as Managing Director on April 1, 2001
• Transitioned to Whole-time Director role on May 3, 2021
• Awarded the Uttarakhand Ratan at the 38th Annual All India Conference of Intellectuals in 2018
• Has family connections within the company including his sons Mr. Hitesh Windlass and Mr. Manoj Kumar Windlass, and daughter-in-law Mrs. Prachi Jain Windlass

Vivek Dhariwal - Independent Director

Mr. Vivek Dhariwal serves as Chairman of the Board and brings over 24 years of industry experience in manufacturing and supply chain operations. His professional background includes:

• Bachelor's Degree in Chemical Engineering from IIT Bombay
• Master's Degree in Chemical Engineering from the University of Kentucky, USA
• Previous leadership roles at prominent companies including ICI India Ltd, Baxter India Private Ltd, and Pfizer Ltd
• No inter-se relationships with other company directors

Gaurav Gulati - Independent Director

Mr. Gaurav Gulati combines academic distinction with industry expertise in his role as Non-Executive Independent Director:

• Bachelor's Degree in Computer Science from the University of Illinois
• MBA from the Booth School of Business, USA
• Previous key leadership roles at Oyo Hotels and Homes Private Limited
• Contributed significantly to business strategy and operations
• No inter-se relationships with other company directors

Regulatory Compliance

The re-appointments comply with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All three directors have been confirmed as not being debarred from holding directorial positions by SEBI or any other regulatory authority. The company has provided comprehensive disclosures as required under SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

The re-appointments ensure continuity in the company's leadership structure while maintaining the required balance of executive and independent directors on the Board.